Cancer is personal. Patient therapy should be too.
Our multimodal AI test personalizes therapy, optimizing treatment decision-making between clinicians and patients.
Developing specialized tools to support personalized clinical care.
Our test predicts therapeutic benefit and provides risk stratification.
Our AI biomarkers can predict therapeutic benefit and prognosticate long-term outcomes to enable cancer therapy personalization.
Randomized phase III trials with thousands of patients and terabytes of imagery are used to develop and validate predictive and prognostic AI biomarkers.
Artera’s test reports are available with a four to five day turnaround time from the date patient samples are received.
We’re passionate about personalizing cancer care.
Driven by integrity, innovation, and the advancement of medical technology, our team of experts is passionate about developing AI tools that help enable clinicians to deliver individualized treatment plans.
Artera News & Events
Artera Launches with $90 Million in Funding to Personalize Cancer Therapy With Multimodal AI
Artera, the developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, launched publicly today with $90M in funding.
The Artera team is attending USCAP 2023 in New Orleans, Louisiana. Come find us at this annual event, which is the largest gathering of pathologists in the world!
How AI can support the American Cancer Society’s IMPACT Initiative
Andre Esteva, Co-founder and CEO of Artera, discusses how AI can support the ACS' IMPACT initiative and other possibilities in the healthcare industry.